Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
1. Detect drug target whole gene precision sequence of everyone patient for all 600 recruited double blind prostate cancer patients. 2. Mutually compare everyone patient drug target whole gene precision sequence for a total of 600 recruited double blind prostate cancer patients. 3. Calculate drug target gene SNPs in all 600 recruited double blind prostate cancer patients. 4. Correlate everyone patient drug target gene SNP to everyone patient drug efficacy. 5. Correlate everyone patient drug target gene SNP to everyone patient drug safety. 6. Mutually compare the usual approach group SNPs (300 double blind random group separated prostate cancer patients) with the study approach group SNPs (300 double blind random group separated prostate cancer patients). 7. Confirm the relationship between drug target gene SNPs and drug efficacy. 8. Confirm the relationship between drug target gene SNPs and drug safety.
Age
22–75
Sex
MALE
Healthy volunteers
Not accepted